Moreover, we reported that MLKL, RIPK3 and Beclin-1 cut-off expression levels higher than 1.973, 1.892- and 1.912-fold expression, respectively, in ITP patients could detect the non-responders, this highlighting that MLKL, RIPK3 and Beclin-1 might be useful in predicting ITP patients that will benefit from steroid therapy. This evidence concerns the gene RIPK3 and autoimmune thrombocytopenic purpura.